1-4 of 4
Susan J. Knox, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma

Holbrook E Kohrt, MD PhD, Jaqueline Chu, MD, Joshua Brody, MD, Debra K Czerwinski, Cariad Chester, Mohith Sadaram, BS, Ranjana Advani, MD, Youn H. Kim, MD, Richard T. Hoppe, MD, Susan J. Knox, MD PhD, Irene Wapnir, MD, Robert J. Tibshirani, PhD, Ron Levy, MD
Journal: Blood
Blood (2014) 124 (21): 3092.
https://doi.org/10.1182/blood.V124.21.3092.3092
Published: 2014
Journal Articles

Phase I, Multicenter, Open Label, Dose Escalation of 90 yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma

Christos Vaklavas, MD, Ruby F Meredith, M.D., Ph.D., Susan J. Knox, MD, PhD, Gregory Wiseman, MD, Thomas E. Witzig, MD, Ivana N. Micallef, MD, Albert F. Lobuglio, MD, Andres Forero, MD
Journal: Blood
Blood (2011) 118 (21): 1648.
https://doi.org/10.1182/blood.V118.21.1648.1648
Published: 2011
Journal Articles

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

Mark S. Kaminski, MD, Andrew D. Zelenetz, MD, Oliver W. Press, MD, PhD, Mansoor N. Saleh, MD, John P. Leonard, MD, Louis Fehrenbacher, MD, T. Andrew Lister, MD, Thierry J. Horner, PhD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Christina Vleisides, DC, Susan J. Knox, MD, PhD, Richard L. Wahl, MD, Julie M. Vose
Journal: Blood
Blood (2010) 116 (21): 3960.
https://doi.org/10.1182/blood.V116.21.3960.3960
Published: 2010
Journal Articles

Tositumomab and Iodine I 131 Tositumomab (The BEXXAR® Therapeutic Regimen) Produced Ongoing, Durable Remissions of More Than 5 Years in 9 Patients with Non-Hodgkin’s Lymphoma (NHL) in a Pivotal Study of Patients Refractory to Their Last Chemotherapy.

Mark S. Kaminski, MD, Andrew D. Zelenetz, MD, Oliver W. Press, MD, Mansoor N. Saleh, MD, John P. Leonard, MD, Louis Fehrenbacher, MD, T. Andrew Lister, MD, Stewart Kroll, PhD, Richard L. Wahl, MD, Susan J. Knox, MD, Julie M. Vose, MD.
Journal: Blood
Blood (2004) 104 (11): 2631.
https://doi.org/10.1182/blood.V104.11.2631.2631
Published: 2004